Korea Accelerating Efforts To Develop, Launch Orphan Drugs
This article was originally published in SRA
Executive Summary
South Korea's Ministry of Food and Drug Safety has issued revised rules to ease the designation and approval of orphan drugs. The changes are expected to create an environment that would support aggressive development of orphan drugs by the domestic pharmaceutical industry and result in more treatment options for patients.
You may also be interested in...
Korea Lowers Medical Cost For Rare Disease Patients, Eases Off-Label Use Rules
In an ongoing effort to improve access to drugs and provide more treatment options for rare disease patients, South Korea unveils new steps to lower their treatment costs and expand the scope of what are considered rare diseases.
Pfizer’s Goettler On What Partners Look For In Orphan Drug Deals
Michael Goettler, Pfizer's global president, rare disease global innovative pharma business, offers tips to Korean orphan drug developers on reaching out to potential partners successfully and what Pfizer is looking for in rare disease deals.
2016 Review: Despite Political Woes, Korea Pro-Pharma Policies Stay Intact
2016 has been full of shock and despair in South Korea’s political scene. But when it comes to the country’s biopharma policy, the year has seen fewer surprising or dramatic events.